We are live on ! Find out more
SRNE

Sorrento Therapeutics, Inc.

Delisted

SRNE was delisted on the 22nd of February, 2023.

88 hedge funds and large institutions have $124M invested in Sorrento Therapeutics, Inc. in 2015 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 27 increasing their positions, 23 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more call options, than puts

Call options by funds: $6.2M | Put options by funds: $2.81M

93% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 14

17% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 23

17% more funds holding

Funds holding: 7588 (+13)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

47% less capital invested

Capital invested by funds: $235M → $124M (-$111M)

Holders
88
Holders Change
+13
Holders Change %
+17.33%
% of All Funds
2.45%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
27
Increased
27
Reduced
23
Closed
14
Calls
$6.2M
Puts
$2.81M
Net Calls
+$3.39M
Net Calls Change
+$2.71M

SRNE Hedge Fund Activity: Q3 2015 in Review

88 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2015, worth a combined $124M — down 47% from $235M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new SRNE positions and 14 closed out — a net gain of 13 holders — while 27 added to existing stakes and 23 trimmed.

The largest buyer was Wildcat Capital Management, adding an estimated $15.5M. The largest seller was Aisling Capital, cutting an estimated $21.5M.

  • 88 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2015, up from 75 in Q2 2015.
  • Funds reported $124M of Sorrento Therapeutics, Inc. stock for Q3 2015, down 47% quarter-over-quarter.
  • 27 funds opened new Sorrento Therapeutics, Inc. positions in Q3 2015 and 14 closed out, a net change of +13 holders.
  • The largest Sorrento Therapeutics, Inc. buyer in Q3 2015 was Wildcat Capital Management, an estimated $15.5M added.
  • The largest Sorrento Therapeutics, Inc. seller in Q3 2015 was Aisling Capital, an estimated $21.5M sold.

Based on aggregated 13F filings for Q3 2015.